Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Frontiers in Oncology
Hui ZhangLung-Ji Chang

Abstract

Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed. Recent research has identified that CLL1 is highly expressed on AML leukemia stem cells and blasts cells but not on normal hematopoietic stem cells. In this case report, we treated a secondary AML patient with anti -CLL1 CAR-T therapy and achieved morphological, immunophenotypic and molecular complete remission for over 10 months. Although only one successful case is presented here, the anti-CLL1 CAR T-cells should be considered as another treatment option for secondary AML in the future.

References

Mar 18, 2011·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collab
Apr 9, 2015·Blood·Felicitas TholArnold Ganser
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Jul 27, 2017·Journal of Hematology & Oncology·Felix S LichteneggerMarion Subklewe
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Jan 11, 2018·Journal of Hematology & Oncology·Jinghua WangPenghui Zhou
Aug 8, 2018·Nature Reviews. Clinical Oncology·Kris M MahadeoUNKNOWN Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Feb 8, 2019·Leukemia·Brooks BenardDaniel Thomas
Apr 24, 2019·Nature Medicine·Zhitao YingSi-Yi Chen
May 6, 2019·Nanomedicine : Nanotechnology, Biology, and Medicine·Tzu-Yin LinBrian A Jonas
May 18, 2019·American Society of Clinical Oncology Educational Book·Michael HeuserJessica K Altman
Jul 20, 2019·Therapeutic Advances in Hematology·Eric S Winer, Richard M Stone
Jul 25, 2019·International Journal of Molecular Sciences·Solène FernandezPierre-Yves Dumas

❮ Previous
Next ❯

Citations

Mar 23, 2021·The Cancer Journal·Florence BorotAbdullah Mahmood Ali
May 1, 2021·International Journal of Molecular Sciences·Jong-Bok LeeLi Zhang
Apr 10, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hui ZhangHua Jiang
Jul 3, 2021·Current Treatment Options in Oncology·Rehan UddinShaker A Mousa
Oct 14, 2021·Cancers·Sargam KapoorMatthew J Olnes
Dec 29, 2021·Pharmaceutical Biology·Jingjing WuYue Chen
Jan 12, 2022·Current Opinion in Hematology·Jan KoedamGerhard Ehninger

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
flow cytometry

Clinical Trials Mentioned

NCT00846703

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.